NCT03094247

Brief Summary

An appropriate balance of omega-6 and omega-3 fatty acids is important for support of neurocognitive development in healthy infants and toddlers. In young children recovering from severe acute malnutrition (SAM), excess omega-6 intake depletes omega-3 fatty acid status. This research will evaluate how novel ready-to-use therapeutic foods (RUTF) with balanced fatty acids improve the metabolic and neurocognitive effects in young children in Malawi recovering from SAM, yielding new knowledge that also has implications for development of well-nourished children.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,897

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 23, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 29, 2017

Completed
6 months until next milestone

Study Start

First participant enrolled

October 2, 2017

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 23, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 23, 2021

Completed
Last Updated

July 19, 2022

Status Verified

July 1, 2022

Enrollment Period

3.5 years

First QC Date

March 23, 2017

Last Update Submit

July 14, 2022

Conditions

Keywords

MalnutritionMicronutrientsPolyunsaturated fatty acidsReady-to-use therapeutic foodsOmega-3 fatty acidsPeanuts

Outcome Measures

Primary Outcomes (2)

  • Neurocognitive outcome

    Measured by score on the Malawian Developmental Assessment Test (MDAT). The scale is continuous and interval in nature, the range varies by population * The scale title is "Malawi Developmental Assessment Tool z-score" * The primary outcome is Global z-score, titled "Global z-sore" * Secondary outcomes are 4 sub-domain z-scores are titled "Gross motor z-score", "Fine motor z-score", Language z-score", and "Social z-score"

    Time Frame: 4 to 7 months after nutritional outcome

  • Neurocognitive outcome

    Defined by Willatts intention score adapted for field training, 3 problems to be tested. The scale is ordinal in nature, with higher values indicated better scores * The scale title is "Intention Score" * Problem 1 is scored 0 - 4 * Problem 2 is scored 0 - 4 * Problem 3 is scored 0 - 8

    Time Frame: within 4 weeks after nutritional outcome

Secondary Outcomes (4)

  • Nutritional recovery

    Up to 12 weeks following enrollment

  • Attentional orienting speed

    4-7 months after nutritional after nutritional outcome

  • Adverse Events

    Fortnightly follow up visits up to 12 weeks following enrollment

  • Acceptance of RUTF

    Fortnightly follow up visits up to 12 weeks following enrollment

Study Arms (3)

Conventional RUTF (S-RUTF)

ACTIVE COMPARATOR

This is the control group for the study, which will receive the international standard of care therapeutic food. S-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.

Drug: AmoxicillinDietary Supplement: S-RUTF

High oleic RUTF (HO-RUTF)

EXPERIMENTAL

The treatment provided to children randomized to this arm of the study includes nutritional content comparable to S-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.

Drug: AmoxicillinDietary Supplement: HO-RUTF

DHA-supplemented HO-RUTF (D-HO-RUTF)

EXPERIMENTAL

The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.

Drug: AmoxicillinDietary Supplement: D-HO-RUTF

Interventions

All patients with severe acute malnutrition will receive a course of amoxicillin.

Also known as: Amoxil
Conventional RUTF (S-RUTF)DHA-supplemented HO-RUTF (D-HO-RUTF)High oleic RUTF (HO-RUTF)
HO-RUTFDIETARY_SUPPLEMENT

HO-RUTF: Milk, perilla oil, palm oil, white sugar, high oleic peanuts

High oleic RUTF (HO-RUTF)
D-HO-RUTFDIETARY_SUPPLEMENT

D-HO-RUTF: DHA, milk, perilla oil, palm oil, white sugar, high oleic peanuts

DHA-supplemented HO-RUTF (D-HO-RUTF)
S-RUTFDIETARY_SUPPLEMENT

S-RUTF: Milk, canola oil, palm oil, white sugar, standard peanuts

Conventional RUTF (S-RUTF)

Eligibility Criteria

Age6 Months - 59 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • months
  • An acceptable appetite defined by the ability to consume 30 grams RUTF within 20 minutes
  • Mid Upper Arm Circumference \<11.5 cm, weight-for-height z-score \< -3, or bilateral pitting edema on the dorsum of the feet

You may not qualify if:

  • Participation in any other ongoing study or supplementary feeding program
  • Children with a chronic medical condition, including cerebral palsy, static encephalopathy, congenital heart disease, gastrointestinal disease, or peanut allergy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Malawi College of Medicine

Blantyre, Malawi

Location

Related Publications (1)

  • Stephenson K, Callaghan-Gillespie M, Maleta K, Nkhoma M, George M, Park HG, Lee R, Humphries-Cuff I, Lacombe RJS, Wegner DR, Canfield RL, Brenna JT, Manary MJ. Low linoleic acid foods with added DHA given to Malawian children with severe acute malnutrition improve cognition: a randomized, triple-blinded, controlled clinical trial. Am J Clin Nutr. 2022 May 1;115(5):1322-1333. doi: 10.1093/ajcn/nqab363.

MeSH Terms

Conditions

Severe Acute MalnutritionMalnutrition

Interventions

Amoxicillin

Condition Hierarchy (Ancestors)

Nutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

AmpicillinPenicillin GPenicillinsbeta-LactamsLactamsAmidesOrganic ChemicalsSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Mark J Manary, MD

    Washington University School of Medicine

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 23, 2017

First Posted

March 29, 2017

Study Start

October 2, 2017

Primary Completion

March 23, 2021

Study Completion

March 23, 2021

Last Updated

July 19, 2022

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will share

Individual participant data that underlie the results reported in the article after deidentification will be indefinitely available within 9 months following article publication through The Washington University Open Scholarship Institutional Repository.

Shared Documents
STUDY PROTOCOL
Time Frame
Data will be available within 9 months of article publication. Data will remain available indefinitely.
Access Criteria
Anyone who wishes to access the data.
More information

Available IPD Datasets

Individual Participant Data Set Access

Locations